Hsbc Holdings PLC Purchases New Shares in Palvella Therapeutics, Inc. $PVLA

Hsbc Holdings PLC purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 50,001 shares of the company’s stock, valued at approximately $7,641,000.

A number of other large investors have also recently bought and sold shares of PVLA. KBC Group NV purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Palvella Therapeutics during the second quarter worth about $35,000. Group One Trading LLC grew its holdings in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the 3rd quarter valued at about $36,000. Finally, Quantbot Technologies LP acquired a new position in Palvella Therapeutics in the 2nd quarter valued at about $71,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Down 0.2%

Shares of NASDAQ:PVLA opened at $149.97 on Friday. Palvella Therapeutics, Inc. has a fifty-two week low of $49.81 and a fifty-two week high of $161.38. The firm’s 50-day simple moving average is $146.01 and its 200-day simple moving average is $126.90. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -31.05 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, research analysts forecast that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on PVLA shares. HC Wainwright reaffirmed a “buy” rating and set a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Stephens reiterated an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Truist Financial set a $207.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Palvella Therapeutics presently has an average rating of “Buy” and an average price target of $209.14.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.